Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human phagocytes.

In this open trial we investigated the effect of pidotimod, a synthetic immunomodulating compound, on human neutrophil and monocyte phagocytic capacity. Twenty healthy volunteers were randomly assigned to two groups of 10 subjects and received. pidotimod 400 mg x 2/die (group A) or 800 mg x 1/die (group B). Already after three days of treatment a significant improvement of neutrophil and monocyte phagocytic capacity was observed in both groups. The enhancement was maintained during the treatment, but substantially disappeared seven days after the end of treatment. These results suggest that pidotimod exerts, at least in part, its clinical effect, i.e. the prevention of recurrent infections, by stimulating phagocytic cell function.